Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with a positive revenue growth outlook, efficient cash management, and a completed share repurchase program. Despite some management vagueness on RFP activity and upsell details, the Q&A reveals positive sentiment towards early commitments and new client utilization. The market cap suggests a moderate reaction, so the stock price is likely to see a positive movement between 2% to 8% over the next two weeks.
Key Financial Performance
First Quarter Revenue Record first quarter revenue came in at the higher end of expectations, reflecting an increase of 1.4% on a reported basis and more than 12% when excluding the contribution from a large former client who was under a transition of care agreement in the first quarter of 2025. The increase was driven by healthy member engagement and utilization trending to the higher end of the historical range.
Gross Margin Gross margin expanded due to efficiencies realized in care management and service delivery as well as the anticipated reduction in stock compensation expense.
Adjusted EBITDA Adjusted EBITDA for the first quarter was strong, reflecting disciplined management and healthy cash flow. The company is raising its full-year expectations for adjusted EBITDA.
Operating Cash Flow Generated approximately $46 million in operating cash flow for the quarter, yielding over $200 million on a trailing 12-month basis. This reflects ongoing focus on process improvement in revenue to cash management.
CapEx First quarter CapEx was $6.3 million, reflecting a $3.5 million increase over the prior year period. This increase is attributed to the ramping of the investment program over the early part of 2025.
DSO (Days Sales Outstanding) DSO improved by 11 days compared to the first quarter of the previous year, even with the customary sequential build from Q4 as new client payment flows were established.
Share Repurchase Program Repurchased more than 5.5 million shares for approximately $160 million during the quarter, completing the $200 million share repurchase program. This reflects the company's flexibility to return value to shareholders.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Platform Capabilities Expansion: Investments made to expand the capabilities of the platform and enhance the member experience.
Progyny Select Offering: Progress with aggregators and distribution partners for Progyny Select, with incremental contributions expected later in the year.
Market Activity: High level of activity and energy in the market, with early commitments pacing ahead of last year.
Cigna Partnership: First full season with Cigna as a partner, showing good inflow of opportunities.
RFP Activity: Significant increase in RFPs from businesses currently with standalone competitors, outpacing last year.
Revenue Growth: Record first-quarter revenue at the higher end of expectations, with a projected 10.1% to 13.3% growth for the full year excluding a former client.
Margin Performance: Healthy margin performance with gross margin expansion and consistent adjusted EBITDA margin.
Cash Flow and Share Repurchase: Generated $46 million in operating cash flow and completed a $200 million share repurchase program.
Renewal Season Derisking: Early favorable notifications from large clients, reducing renewal exposure to its lowest level compared to prior years.
Focus on Family Building Solutions: Emphasis on cost-effective family building and women's health solutions as a priority for employers.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Member engagement variability: Unexpected variability in member engagement and treatment activity could occur, potentially impacting revenue and operational planning.
Renewal exposure: Although renewal exposure is at its lowest level compared to prior years, there is still a risk associated with securing renewals for the remaining book of business.
Dependence on large clients: The company has a history of losing large clients, as evidenced by the loss of a major client two years ago, which could impact revenue stability.
Economic uncertainties: Concerns about macroeconomic factors such as inflation, tariffs, and potential recessions could pose risks to the company's growth and financial performance.
AI-driven labor market changes: Potential disruptions in the labor market due to AI could impact employer demand for family-building benefits, although the company currently sees no signs of this.
Transition of care agreements: Revenue comparisons are impacted by the transition of care agreements with former clients, which could create challenges in maintaining growth rates.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Financial Outlook for 2026: The company has issued guidance for the second quarter and full year 2026, projecting revenue of $1.365 billion to $1.405 billion for the year, reflecting growth of 5.9% to 9%. Excluding revenue from a transitioning client, growth is projected at 10.1% to 13.3%. Adjusted EBITDA is expected to range from $232 million to $244 million, with net income between $103.7 million and $112.3 million. Earnings per diluted share are projected at $1.23 to $1.34, and adjusted EPS at $1.98 to $2.09.
Second Quarter 2026 Guidance: Revenue is projected between $342 million and $355 million, reflecting growth of 2.7% to 6.6%. Excluding revenue from a transitioning client, growth is projected at 8.3% to 12.4%. Adjusted EBITDA is expected to range from $58 million to $62 million, with net income between $25.8 million and $28.7 million. Earnings per diluted share are projected at $0.31 to $0.35, and adjusted EPS at $0.50 to $0.53.
Utilization and ART Cycle Assumptions: The company maintains its full-year utilization assumption of 1.04% to 1.05% and ART cycle consumption per female unique at 0.93 to 0.95. A sequential increase in utilization is expected in the second quarter.
Market Trends and Employer Demand: The company expects continued demand for family building and women's health solutions, driven by macro trends such as declining birth rates among younger women and increasing birth rates among women aged 30 and over. Employers are prioritizing cost-effective solutions to address infertility and family building needs.
Pipeline and Sales Activity: Early sales commitments and pipeline activity are favorable compared to the previous year. The company has derisked the renewal season with early favorable notifications from large clients and is seeing strong activity from RFPs, particularly from business currently with competitors.
Partnerships and Distribution Channels: The company is seeing good traction with health plan partners, including Cigna, and progress with aggregators and distribution partners for the Progyny Select offering. Incremental contributions to the pipeline from these channels are expected later in the year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program Completion: Progyny Inc. completed its $200 million share repurchase program, repurchasing approximately 8.8 million shares in total. This program began in November and concluded during the quarter.
Potential New Share Repurchase Program: The Board of Progyny Inc. is evaluating options for a new share repurchase program. A decision is anticipated by the end of May, with an announcement expected at that time.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are early sales commitments split between 'not nows' from last year and new employers?
A:A higher proportion of early commitments come from 'not nows' from last year. Overall, the activity and commitments are positive compared to last year.
Q:Are there consistent themes driving more RFP activity from competitor clients?
A:No specific constructive themes were shared. The focus is on the increased level of activity compared to previous years.
Q:Have there been changes in the process to avoid surprises in membership changes?
A:Yes, the company is now obtaining full eligibility files from clients instead of just numeric headcount updates. By year-end, they expect to have eligibility files from the majority of clients.
Q:What drove the increase in revenues per ART Cycle?
A:The increase is due to a higher proportion of new clients in the initial consultation phase, which generates revenue without ART Cycles. This was less evident last year due to a large client under a transition of care program.
Q:What is the update on new products and upsell activity?
A:Upsell activity is positive but too early to provide more details. Investments are focused on additional capabilities for existing products rather than entirely new products.
Q:What is embedded in the guidance for upselling of new products?
A:The guidance includes only already committed activities. Upsell activity is expected to impact materially in the following year.
Q:What drove higher utilization among new clients?
A:Higher utilization is due to a higher contribution of certain industries in the new cohort. Overall, utilization is performing as expected.
Q:What further investments are needed throughout the year, and is there potential upside to margin guidance?
A:Investments are already phased throughout the year and factored into guidance. Efficiencies gained in Q1 are recurring and have been included in the updated guidance.
Q:Are early pipeline sales coming from 'not nows' in past years, and why the uptick this year?
A:Yes, a higher proportion of early commitments come from 'not nows.' The uptick may be due to a later pipeline build last year.
Q:What is the mix of client demand between case rate and back-end savings?
A:The current model focuses on case rates and has been effective. There are no plans to shift to a back-end savings model.
Q:What was the revenue growth in Q1 excluding the impact of one major client?
A:Revenue growth was slightly more than 12%.
Q:Are existing clients adding employees, and is there any impact from external factors like the Iran war?
A:Existing client employee counts are relatively flat. The Iran war has not impacted engagement or other metrics.
Q:What is the market reception to the Select product?
A:The reception is positive, with aggregators and distributors signing up. Pull-through is expected by the end of the year.
Q:What is the growth rate for ART Cycles in the market?
A:The growth rate remains consistent with historical data, around 10% CAGR. No new data suggests a change in this rate.
Q:What were the true-ups on the administrative side this quarter?
A:True-ups were typical, with some clients up and others down, largely offsetting each other. Efforts are underway to refine processes and avoid future adjustments.
Q:Is there anything different about the value proposition resonating this selling season?
A:No substantial differences. The focus remains on managing individual outcomes and overall program cost containment.
Q:What drove the strong non-GAAP gross profit margin in the quarter?
A:Lower stock compensation expenses and recurring efficiencies contributed to the strong margin, which is expected to continue throughout the year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific constructive themes driving RFP activity from competitor clients and did not share detailed expectations for upsell activity or new product launches. Additionally, they did not provide updated data on ART Cycle market growth rates beyond historical trends.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI headcount
AI point
CDC number
CFOs AI
Cigna partner
Progyny Select
activity RFPs
age
birth rate
building woman
channel
claim warehouse
concern
decision
employer cost
evidence
expectation income
fertility pregnancy
group
level activity
outcome
pattern
potential
priority
progress
range
rate woman
reason
record
renewal season
repurchase program
review
season notification
share repurchase
traction
trend
valuation
value
PGNY Transcript
Progyny, Inc. (PGNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call indicates strong financial performance with a positive revenue growth outlook, efficient cash management, and a completed share repurchase program. Despite some management vagueness on RFP activity and upsell details, the Q&A reveals positive sentiment towards early commitments and new client utilization. The market cap suggests a moderate reaction, so the stock price is likely to see a positive movement between 2% to 8% over the next two weeks.
Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call shows strong financial performance with a 20% revenue growth excluding a large client, a double-digit increase in EBITDA, and a significant rise in operating cash flow. Share repurchases further indicate confidence. Despite some margin compression and conservative guidance, the company is expanding its product offerings and has a positive outlook on membership and revenue growth. The Q&A section reveals some uncertainties, but overall sentiment remains positive. Given the company's market cap, a 2% to 8% stock price increase is likely over the next two weeks.
PGNY Slides
PGNY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
